Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Yi-Syuan Sun, De-Feng Huang, Fu-Pang Chang, Wei-Sheng Chen, Hsien-Tzung Liao, Ming-Han Chen, Hung-Cheng Tsai, Ming-Tsun Tsai, Chang-Youh Tsai, Chien-Chih Lai, Chih- Yu Yang
OBJECTIVE: To evaluate the risk of end-stage kidney disease (ESKD) in lupus nephritis (LN) patients using tubulointerstitial lesion scores. METHODS: Clinical profiles and histopathological presentations of 151 biopsy-proven LN patients were retrospectively examined. Risk factors of ESKD based on characteristics and scoring of their tubulointerstitial lesions (e.g. interstitial inflammation [II], tubular atrophy [TA], and interstitial fibrosis [IF]) were analyzed...
May 2, 2024: Rheumatology
#22
JOURNAL ARTICLE
Sara T Patrizi, Megha D Tandel, Derek Boothroyd, Julia F Simard, Joyce J Hsu
OBJECTIVE: In 2019, the EULAR/American College of Rheumatology developed classification criteria for systemic lupus erythematosus (SLE). A positive correlation between summary score at diagnosis and SLE disease activity at five years has been noted in adult patients with lupus, but little is known among the pediatric population. We evaluated the prognostic value of higher summary scores and number of extrarenal domains at diagnosis (low/moderate number [1-5] vs high number [6-9]) to renal outcomes after one year of treatment in pediatric patients with lupus nephritis (LN)...
May 2, 2024: ACR open rheumatology
#23
JOURNAL ARTICLE
Ji-Ning Jia, Xian-Li Wang
Introduction: We investigated trends in the use of therapeutic drugs for pregnant patients with rheumatic diseases in nine Chinese cities (Beijing, Chengdu, Guangzhou, Harbin, Hangzhou, Shanghai, Shenyang, Tianjin, and Zhengzhou) to provide a reference for drug use in clinic. Methods: Outpatient prescription data for pregnant patients diagnosed with rheumatic diseases in nine cities across China in 2016-2021 were extracted from the Hospital Prescription Cooperation Project of the Hospital Pharmacy Professional Committee of the Chinese Pharmaceutical Association...
2024: Frontiers in Pharmacology
#24
Ghina Haidar, Naram Khalayli, Tasneem Drie, Mhd Homam Safiah, Maysoun Kudsi
INTRODUCTION: Systemic lupus erythematosus (SLE) is a systemic immune disease that classically occurs in young to middle-aged women and may present with cutaneous, renal, haematologic, neurological, and/or other symptoms at the time of diagnosis. Late-onset SLE or SLE in the elderly is a subtype that differs from classic SLE in terms of age group, clinical symptoms, organ involvement and severity. CASE PRESENTATION: A 63-year-old female noted to have pancytopenia...
May 2024: Annals of Medicine and Surgery
#25
REVIEW
Himanshu Arora, Binish Javed, L V Simhachalam Kutikuppala, Mayuri Chaurasia, Kaarvi Khullar, Shreevikaa Kannan, Varshitha Golla
Interleukin-33 (IL-33), belonging to the interleukin-1 cytokine family, has a decoy receptor soluble ST2 (sST2). IL-33 is found in oligodendrocytes and astrocytes and is involved in central nervous system healing and repair, whereas ST2 is found in microglia and astrocytes. Some studies have found a link between changes in the IL-33/ST2 pathway and neurodegenerative disorders. This review article investigates the relationship between the interleukin-33 (IL-33)/ST2 pathway and neurodegenerative disorders. It was discovered that soluble st2 levels were increased...
May 2024: Annals of Medicine and Surgery
#26
Timothy Nguyen, Stephen Wanjala, Abdul Rahman Akkawi, Kyle Rowe, Basit Malik
No abstract text is available yet for this article.
2024: Kansas Journal of Medicine
#27
JOURNAL ARTICLE
Ahmed H Al-Jedai, Hajer Y Almudaiheem, Ibrahim A Al-Homood, Ibrahim Almaghlouth, Sami M Bahlas, Abdulaziz Mohammed Alolaiw, Mohammad Fatani, Maysa Tariq Eshmawi, Bedor A AlOmari, Khalidah Ahmed Alenzi, Rayan G Albarakat, Nayef Al Ghanim
OBJECTIVE: To provide evidence-based clinical practice recommendations for managing Systemic Lupus Erythematosus (SLE) in Saudi Arabia. METHODS: This EULAR-adapted national guideline in which a multidisciplinary task force utilized the modified Delphi method to develop 31 clinical key questions. A systematic literature review was conducted to update the evidence since the EULAR publication. After reaching a consensus agreement, two rounds of voting and group discussion were conducted to generate consolidated recommendations/statements...
April 30, 2024: Current Rheumatology Reviews
#28
REVIEW
Dana Auyezkhankyzy, Umida Khojakulova, Marlen Yessirkepov, Ainur B Qumar, Olena Zimba, Burhan Fatih Kocyigit, Mazlum Serdar Akaltun
Nurses have become integral members of multidisciplinary teams in managing rheumatic diseases, departing from their traditional patient care roles. This article provides a comprehensive review of nurses' roles, interventions, and impacts in several rheumatic diseases, including rheumatoid arthritis, osteoarthritis, spondyloarthritis, gout, systemic lupus erythematosus, and polymyalgia rheumatica. It has been demonstrated that care under nursing supervision is effective and safe, with benefits including disease management, quality of life, and treatment adherence...
May 2, 2024: Rheumatology International
#29
REVIEW
Xuefei Wang, Guo-Min Deng
Moderate-to-severe systemic lupus erythematosus (SLE) is characterized by extensive autoantibody deposition and persistent autoinflammation. As the existing animal models are limited in accurately reproducing the pathological characteristics of human SLE, we introduced a novel animal model simulating multi-organ autoinflammation through intra-organ injections. The model closely mimicked key features of SLE, including IgG deposition, inflammation, and tissue damage. The model could be used to assess the roles of IgG, immune cells, cytokines, and Fc gamma receptor (FcγR) in the pathogenesis of autoinflammation...
April 29, 2024: Clinical Immunology: the Official Journal of the Clinical Immunology Society
#30
Dongjie Yu, Yuansen Luo, Linlin Sun
We report a case of septic arthritis in a 43-year-old female patient. Despite initial treatment with ceftriaxone for Nontyphoidal Salmonella based on blood and joint fluid culture results, the shoulder joint pain worsened. Suspected systemic lupus erythematosus associated synovitis did not respond to immunosuppressive therapy including methylprednisolone, hydroxychloroquine and methotrexate. Subsequent radiograph revealed a shoulder joint abscess, leading to arthroscopic joint debridement. Ceftriaxone was administered post-operatively until analgesic efficacy was attained...
April 27, 2024: Diagnostic Microbiology and Infectious Disease
#31
JOURNAL ARTICLE
Baozhen Huang, Huiyu Li, Qian Jiang, Yucong Li, Zhaowei Jiang, Huijuan Cao, Shaoxi Wang, Xinluan Wang, Jianguo Li, Gang Li
The link between type I IFN and adaptive immunity, especially T-cell immunity, in JDM still remained largely unclear. This study aimed to understand the effect of elevated type I IFN signaling on CD8+ T cell-associated muscle damage in juvenile dermatomyositis (JDM). This study used flow cytometry (FC) and RT‒PCR were used to examine the circulating cell ratio and type I IFN response. And scRNA-seq was used to examine peripheral immunity in 6 active JDM patients, 3 stable JDM patients, 3 juvenile IMNM patients and 3 age-matched healthy children...
April 30, 2024: Journal of Autoimmunity
#32
REVIEW
Shumei Cao, Jiao Jiang, Haoyuan Yin, Lai Wang, Qianjin Lu
Systemic lupus erythematosus (SLE) is a severe autoimmune disease with significant socioeconomic impact worldwide. Orderly energy metabolism is essential for normal immune function, and disordered energy metabolism is increasingly recognized as an important contributor to the pathogenesis of SLE. Disorders of energy metabolism are characterized by increased reactive oxygen species, ATP deficiency, and abnormal metabolic pathways. Oxygen and mitochondria are critical for the production of ATP, and both mitochondrial dysfunction and hypoxia affect the energy production processes...
April 30, 2024: International Immunopharmacology
#33
JOURNAL ARTICLE
Fátima Raad, Paula Luque, Sofía García Ledo, Alicia Alda Lozano, Víctor Llorens, Antonio Espejo, Henar Heras, Lucía Santana, Luis Trapiella, Patricia Fanlo, Alfredo Adán, Gerard Espinosa, Nuria Navarrete
OBJECTIVE: To describe the efficacy and safety of adalimumab for the treatment of non-infectious uveitis (NIU) in four Uveitis Units from tertiary Spanish hospitals. METHODS: Multicenter and retrospective clinical cohort study including all patients with NIU treated with adalimumab from January 2012 to October 2022 in four uveitis units was performed. Efficacy was measured with the number of relapses, ocular inflammation and reduction in immunosuppression and corticosteroid dosage before and after adalimumab use...
May 1, 2024: Ocular Immunology and Inflammation
#34
REVIEW
Ziyad Alakkas, Abdulaziz M Gari, Sara Makhdoum, Eman A AlSindi
BACKGROUND: Mycophenolate mofetil (MMF) is an immunosuppressive drug that is frequently prescribed to patients with rheumatological diseases. MMF's side effects include abdominal discomfort, nausea, vomiting, and other gastro-intestinal side effects, which typically appear in the first few months of treatment. However, late-onset diarrhea does not rule out the presence of MMF-induced colitis, which can be misdiagnosed since it is linked to a broad range of histopathological characteristics, including alterations that resemble inflammatory bowel disease, graft-versus-host disease, and ischemia...
May 1, 2024: Journal of Medical Case Reports
#35
JOURNAL ARTICLE
Marie Jaïs, Pascal Roblot, François Maillot, Mohamed Hamidou, Antoine Enfrein, Alain Lescoat, Mathieu Puyade, Mickaël Martin, Amandine Perier
Data about the impact of Belimumab on corticosteroid sparing in real life are scarce. To assess the corticosteroid-sparing effect among patients with systemic lupus erythematosus (SLE) treated with Belimumab in real-life settings. Multicentric observational retrospective study including patients with SLE and having received Belimumab for at least 6 months between 2011 and 2020, in eight French hospitals. "Low dose" referred to patients receiving up to 7.5 mg of prednisone a day and "Very low dose" to those receiving strictly ≤ 5 mg prednisone a day The primary endpoint was the reduction of daily prednisone dose after six months of Belimumab...
April 30, 2024: Rheumatology International
#36
JOURNAL ARTICLE
José Alcides Almeida de Arruda, Mariana Villarroel-Dorrego, Clara Herrera Freire, Ignacio Molina-Ávila, Juan Martin Pimentel-Solá, Gerardo Gilligan, Eduardo Piemonte, René Panico, Juan Cruz Romero Panico, Saray Aranda-Romo, Francisco Javier Tejeda-Nava, Mônica Simões Israel, John Lennon Silva Cunha, Vanessa Alves de Medeiros, Cassiano Francisco Weege Nonaka, Pollianna Muniz Alves, Israel Leal Cavalcante, José Victor Lemos Ventura, Fernanda Silva de Lima, Victor Zanetti Drumond, Lucas Guimarães Abreu, Tarcília Aparecida Silva, Felipe Paiva Fonseca, Ricardo Alves Mesquita, René Martínez-Flores, Karina Cordero-Torres, Richard Ahumada-Ossandón, Jorge Guzmán, Raiza Toro, José Cândido Caldeira Xavier-Júnior, Sebastião Silvério Sousa-Neto, Diego Antônio Costa Arantes, Elismauro Francisco Mendonça, Victor de Mello Palma, Márcia Gaiger de Oliveira, Fernanda Visioli, Karem L Ortega, Jefferson R Tenório, Bruno Augusto Benevenuto de Andrade
BACKGROUND: Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease that may affect the oral mucosa. The variable spectrum of oral lesions observed in SLE can pose challenges in diagnosis, particularly when the lesions occur in isolation. The aim of this study was to describe the oral lesions occurring in patients with SLE from Latin America. METHODS: This collaborative record-based study involving 11 oral and maxillofacial pathology and medicine services across Venezuela, Argentina, Chile, Brazil, and Mexico describes the clinicopathological profile of SLE-related oral lesions...
April 30, 2024: Lupus
#37
Fieke W Hoff, Chao Xing, Abhimanyu Garg
Acquired generalized lipodystrophy (AGL) is an extremely rare disease that is characterized by loss of body fat affecting nearly all parts of the body. It is often associated with autoimmune diseases or panniculitis, whereas in other patients the underlying etiology is unclear. We report a 52-year-old male individual who was diagnosed with subcutaneous panniculitis-like T-cell lymphoma (SPTCL) that spontaneously went into remission. Years later he developed new subcutaneous nodules most concerning for relapse SPTCL or lupus panniculitis, followed by onset of hemophagocytic lymphohistiocytosis (HLH) that was treated with allogeneic stem cell transplantation...
May 2024: JCEM Case Rep
#38
Harshitha Reddy, Pranjal Kashiv, Sunil Kumar, Kapil N Sejpal, Sourya Acharya
The autoimmune connective tissue disease scleroderma is characterized by fibrosis of the skin, blood vessels, and visceral organs. Overlap syndromes are conditions in which a patient has characteristics from two or more autoimmune disorders. The coexistence of scleroderma and lupus nephritis is rare but documented. However, it is crucial to note that both scleroderma and lupus are complex autoimmune diseases with diverse clinical presentations and can affect multiple organ systems, including the kidneys. This case report presents a unique clinical scenario of a patient with the coexistence of scleroderma and systemic lupus erythematosus with Class V lupus nephritis, highlighting the challenges in diagnosis, treatment, and the need for a multidisciplinary approach...
March 2024: Curēus
#39
Sreethish Sasi, Mugahid Eltahir, Ezzeddin Ibrahim, Aishwariya Padmakumari, Jouhar Kolleri, Tasneem Abdallah, Ahmed Labib Shehatta, Nawal Hadwan, Hani Jaouni, Muna Al-Maslamani
KEY CLINICAL MESSAGE: Hepatic micro-abscesses can be a rare initial presentation of systemic lupus erythematosus (SLE). This case highlights the importance of considering autoimmune etiologies when infectious causes are ruled out and emphasizes the need for early recognition and appropriate treatment of atypical hepatic manifestations in SLE to achieve favorable outcomes. ABSTRACT: Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs, including the liver...
May 2024: Clinical Case Reports
#40
JOURNAL ARTICLE
Jan Miroslav Hartinger, Martin Šíma, Zdenka Hrušková, Alena Pilková, Vojtěch Krátký, Romana Ryšavá, Eva Jančová, Daniel Bobek, Jiří Douša, Ivana Francová, Vladimír Tesař, Ondřej Slanař
OBJECTIVES: Rituximab is being increasingly prescribed for the treatment of autoimmune glomerular diseases. While it is highly effective for some diseases, the response is less predictable for others, which may be due to differing requirements in terms of the dosing according to the disease type and variations concerning exposure to the drug. METHODS: We compiled novel rituximab dosing schedules according to pharmacokinetic analysis of data gathered from rituximab treated patients in a tertiary referral nephrology centre between May 2020 and June 2023...
April 27, 2024: Biomedicine & Pharmacotherapy
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
